HDLs, diabetes, and metabolic syndrome

Handbook of Experimental Pharmacology

Volumn 224, Issue , 2015, Pages 405-421

  Vollenweider, Peter ^a   von Eckardstein, Arnold ^b   Widmann, Christian ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Diabetes; HDLs; Metabolic syndrome

Indexed keywords

ADIPONECTIN; AMYLOID PROTEIN; CHYLOMICRON; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; BODY MASS; CARDIOVASCULAR MORTALITY; CATABOLISM; CELL SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM STRESS; EPIDEMIC; GENE TRANSFER; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; SKELETAL MUSCLE; WEIGHT GAIN; ANIMAL; BLOOD; METABOLISM; PANCREAS ISLET BETA CELL; PROTECTION; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; LIPOPROTEINS, HDL; METABOLIC SYNDROME X; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS;

EID: 84919609120     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-319-09665-0_12     Document Type: Conference Paper

References (87)

1. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann C, Waeber G (2007) Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic b cells. Diabetologia 50:1304–1314
2. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12:141–146
3. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, Kastelein JJ (2011) Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 124:555–562
4. Besler C, Luscher TF, Landmesser U (2012) Molecular mechanisms of vascular effects of Highdensity lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4:251–268
5. Biden TJ, Robinson D, Cordery D, Hughes WE, Busch AK (2004) Chronic effects of fatty acids on pancreatic b-cell function: new insights from functional genomics. Diabetes 53(Suppl 1): S159–S165
6. Borggreve SE, De VR, Dullaart RP (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33:1051–1069
7. Bray GA (1996) Methods and obesity research: the radioimmunoassay of insulin. Obes Res 4:579–582
8. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95–96
9. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR (2007) b-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 13:340–347
10. Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, de Arruda Cardoso SM (2009) Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med 9:319–325
11. Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD (2000) Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production. Am J Physiol Endocrinol Metab 279:E1003–E1011
12. Chorev M, Goodman M (1995) Recent developments in retro peptides and proteins – an ongoing topochemical exploration. Trends Biotechnol 13:438–445
13. Cnop M, Hannaert JC, Grupping AY, Pipeleers DG (2002) Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143:3449–3453
14. Di AE, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000
15. Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Court FJM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA (2009) High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119:2103–2111
16. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA (2012) The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 8:237–245
17. Eisenberg S (1984) High density lipoprotein metabolism. J Lipid Res 25:1017–1058
18. Eizirik DL, Cnop M (2010) ER stress in pancreatic beta cells: the thin red line between adaptation and failure. Sci Signal 3:e7
19. Eizirik DL, Cardozo AK, Cnop M (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29:42–61
20. Fischer PM (2003) The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 4:339–356
21. Fried SK, Russell CD, Grauso NL, Brolin RE (1993) Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 92:2191–2198
22. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA (2010) Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 30:1642–1648
23. Ginsberg HN (1998) Lipoprotein physiology. Endocrinol Metab Clin North Am 27:503–519
24. Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59:635–643
25. Han R, Lai R, Ding Q, Wang Z, Luo X, Zhang Y, Cui G, He J, Liu W, Chen Y (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50:1960–1968
26. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131
27. Inzucchi SE (2012) Clinical practice. Diagnosis of diabetes. N Engl J Med 367:542–550
28. Kang MH, Zhang LH, Wijesekara N, de Haan W, Butland S, Bhattacharjee A, Hayden MR (2013) Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler Thromb Vasc Biol 33:2724–2732
29. Koseki M, Matsuyama A, Nakatani K, Inagaki M, Nakaoka H, Kawase R, Yuasa-Kawase M, Tsubakio-Yamamoto K, Masuda D, Sandoval JC, Ohama T, Nakagawa-Toyama Y, Matsuura F, Nishida M, Ishigami M, Hirano K, Sakane N, Kumon Y, Suehiro T, Nakamura T, Shimomura I, Yamashita S (2009) Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 16:292–296
30. Kruit JK, Wijesekara N, Fox JE, Dai XQ, Brunham LR, Searle GJ, Morgan GP, Costin AJ, Tang R, Bhattacharjee A, Johnson JD, Light PE, Marsh BJ, Macdonald PE, Verchere CB, Hayden MR (2011) Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes 60:3186–3196
31. Kruit JK, Wijesekara N, Westwell-Roper C, Vanmierlo T, de Haan W, Bhattacharjee A, Tang R, Wellington CL, LutJohann D, Johnson JD, Brunham LR, Verchere CB, Hayden MR (2012) Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function. Diabetes 61:659–664
32. Laios K, Karamanou M, Saridaki Z, Androutsos G (2012) Aretaeus of Cappadocia and the first description of diabetes. Hormones (Athens) 11:109–113
33. Lehti M, Donelan E, Abplanalp W, Al-Massadi O, Habegger KM, Weber J, Ress C, Mansfeld J, Somvanshi S, Trivedi C, Keuper M, Ograjsek T, Striese C, Cucuruz S, Pfluger PT, Krishna R, Gordon SM, Silva RA, Luquet S, Castel J, Martinez S, D’Alessio D, Davidson WS, Hofmann SM (2013) High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice. Circulation 128:2364–2371
34. Li N, Fu J, Koonen DP, Kuivenhoven JA, Snieder H, Hofker MH (2014) Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? Atherosclerosis 233:130–138
35. Like AA, Chick WL (1970) Studies in the diabetic mutant mouse. II. Electron microscopy of pancreatic islets. Diabetologia 6:216–242
36. Lin MC, Gordon D, Wetterau JR (1995) Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 36:1073–1081
37. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY (2001) Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 50:69–76
38. Malmstrom R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR (1997a) Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 40:454–462
39. Malmstrom R, Packard CJ, Watson TD, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen MR (1997b) Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454–1464
40. Mann CJ, Yen FT, Grant AM, Bihain BE (1991) Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 88:2059–2066
41. Marsh BJ, Mastronarde DN, Buttle KF, Howell KE, McIntosh JR (2001) Organellar relationships in the Golgi region of the pancreatic beta cell line, HIT-T15, visualized by high resolution electron tomography. Proc Natl Acad Sci USA 98:2399–2406
42. Michod D, Annibaldi A, Schaefer S, Dapples C, Rochat B, Widmann C (2009) Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice. J Natl Cancer Inst 101:828–832
43. Morcillo S, Cardona F, Rojo-Martinez G, Esteva I, Ruiz-de-Adana MS, Tinahones F, Gomez- Zumaquero JM, Soriguer F (2005) Association between MspI polymorphism of the APO AI gene and type 2 diabetes mellitus. Diabet Med 22:782–788
44. Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NC (1998) Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 273:18959–18965
45. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM (2005) Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25:1325–1331
46. Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, Goldstein JL, Brown MS (2001) Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 98:6027–6032
47. Oyadomari S, Araki E, Mori M (2002) Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells. Apoptosis 7:335–345
48. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L’Abbate A, Abraham NG (2009) The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 50:1293–1304
49. Petremand J, Bulat N, Butty AC, Poussin C, Rutti S, Au K, Ghosh S, Mooser V, Thorens B, Yang J-Y, Widmann C, Waeber G (2009) Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta cells. Mol Endocrinol 23:1572–1586
50. Petremand J, Puyal J, Chatton JY, Duprez J, Allagnat F, Frias M, James RW, Waeber G, Jonas JC, Widmann C (2012) HDLs protect pancreatic beta-cells against ER stress by restoring protein folding and trafficking. Diabetes 61:1100–1111
51. Puyal J, Petremand J, Dubuis G, Rummel C, Widmann C (2013) HDLs protect the MIN6 insulinoma cell line against tunicamycin-induced apoptosis without inhibiting ER stress and without restoring ER functionality. Mol Cell Endocrinol 381:291–301
52. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116:3090–3100
53. Rashid S, Watanabe T, Sakaue T, Lewis GF (2003) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36:421–429
54. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, Khatsenko OG, Kaimal V, Lees CJ, Fernandez-Hernando C, Fisher EA, Temel RE, Moore KJ (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:404–407
55. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607
56. Reaven GM (2005) Why Syndrome X? From Harold Himsworth to the insulin resistance syndrome. Cell Metab 1:9–14
57. Roehrich ME, Mooser V, Lenain V, Herz J, Nimpf J, Azhar S, Bideau M, Capponi A, Nicod P, Haefliger JA, Waeber G (2003) Insulin-secreting b-cell dysfunction induced by human lipoproteins. J Biol Chem 278:18368–18375
58. Rohrer L, Hersberger M, von Eckardstein A (2004) High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269–278
59. Ruan X, Li Z, Zhang Y, Yang L, Pan Y, Wang Z, Feng GS, Chen Y (2011) Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and up-regulation of UCP1 in brown fat. J Cell Mol Med 15:763–772
60. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, Meier DT, Niclauss N, Berney T, Donath MY, von Eckardstein A (2009) Low and high-density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic beta cells. Endocrinology 150:4521–4530
61. Rye KA, Barter PJ (2012) Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim Biophys Acta 1821:473–480
62. Schou J, Tybjaerg-Hansen A, Moller HJ, Nordestgaard BG, Frikke-Schmidt R (2012) ABC transporter genes and risk of type 2 diabetes: a study of 40,000 individuals from the general population. Diabetes Care 35:2600–2606
63. Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced b cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498–2502
64. Siebel AL, Natoli AK, Yap FY, Carey AL, Reddy-Luthmoodoo M, Sviridov D, Weber CI, Meneses-Lorente G, Maugeais C, Forbes JM, Kingwell BA (2013) Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 113:167–175
65. Sturek JM, Castle JD, Trace AP, Page LC, Castle AM, Evans-Molina C, Parks JS, Mirmira RG, Hedrick CC (2010) An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. J Clin Invest 120:2575–2589
66. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215–2221
67. Tan KC, Shiu SW, Chu BY (1999) Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with noninsulin- dependent diabetes mellitus. Atherosclerosis 145:273–278
68. Tang C, Oram JF (2009) The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes. Biochim Biophys Acta 1791:563–572
69. Taskinen MR (2003) Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733–749
70. Uehara Y, Engel T, Li Z, Goepfert C, Rust S, Zhou X, Langer C, Schachtrup C, Wiekowski J, Lorkowski S, Assmann G, von Eckardstein A (2002) Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes 51:2922–2928
71. Uehara Y, Miura S, von Eckardstein A, Abe S, Fujii A, Matsuo Y, Rust S, Lorkowski S, Assmann G, Yamada T, Saku K (2007) Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis 191:11–21
72. Umemoto T, Han CY, Mitra P, Averill MM, Tang C, Goodspeed L, Omer M, Subramanian S, Wang S, Den Hartigh LJ, Wei H, Kim EJ, Kim J, O’Brien KD, Chait A (2013) Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 112:1345–1354
73. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, Buga GM, Fogelman AM (2009) Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 11:52–57
74. Van Linthout S, Foryst-Ludwig A, Spillmann F, Peng J, Feng Y, Meloni M, Van Craeyveld E, Kintscher U, Schultheiss HP, De GB, Tschope C (2010) Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis 210:438–444
75. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kastelein JJ, Hayden MR, Stroes ES (2010) Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 33:869–874
76. Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, Villalobos-Comparan M, Rodriguez-Cruz M, Miliar-Garcia A, Huertas-Vazquez A, Menjivar M, Romero-Hidalgo S, Wacher NH, Tusie-Luna MT, Cruz M, Aguilar-Salinas CA, Canizales-Quinteros S (2008) Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in a Mexican population. Diabetes 57:509–513
77. Volchuk A, Ron D (2010) The endoplasmic reticulum stress response in the pancreatic beta-cell. Diabetes Obes Metab 12(Suppl 2):48–57
78. von Eckardstein A, Sibler RA (2011) Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 22:26–32
79. von Eckardstein A, Widmann C (2014) HDL, beta cells and diabetes. Cardiovasc Res 103 (3):384–394
80. von Eckardstein A, Schulte H, Assmann G (2000) Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 85:3101–3108
81. Wang Y, Oram JF (2005) Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway. J Biol Chem 280:35896–35903
82. Wang Y, Oram JF (2007) Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase Cd pathway. J Lipid Res 48:1062–1068
83. Wang S, Peng D (2012) Regulation of adipocyte autophagy – the potential anti-obesity mechanism of high density lipoprotein and ApolipoproteinA-I. Lipids Health Dis 11:131
84. Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, Verchere CB, Hayden MR (2012) miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 61:653–658
85. Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Takahashi A, Sone H, Osuga JJ, Gotoda T, Ishibashi S, Yamada N (2002) Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem 277:1705–1711
86. Zhang Y, McGillicuddy FC, Hinkle CC, O’Neill S, Glick JM, Rothblat GH, Reilly MP (2010) Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121:1347–1355
87. Zhang Q, Zhang Y, Feng H, Guo R, Jin L, Wan R, Wang L, Chen C, Li S (2011) High density lipoprotein (HDL) promotes glucose uptake in adipocytes and glycogen synthesis in muscle cells. PLoS ONE 6:e23556